Device could end diabetes pinpricks.Nearly 16 million people in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. have diabetes, and most need to prick a finger daily with a sterile pin to monitor their blood-glucose concentrations. A new experimental device may take the sting out of this ritual by absorbing moisture through the skin and analyzing it for glucose. The gadget, called GlucoWatch, looks something like a wristwatch with an absorbent absorbent /ab·sor·bent/ (-sor´bent) 1. able to take in, or suck up and incorporate. 2. a tissue structure involved in absorption. 3. a substance that absorbs or promotes absorption. pad underneath it. When tested on 28 individuals who have diabetes, the GlucoWatch readings closely tracked those obtained by pinpricks, says Satish K. Garg of the University of Colorado University of Colorado may refer to:
No device now on the market can continuously monitor blood glucose blood glucose Diabetology The principal sugar produced by the body from food–especially carbohydrates, but also from proteins and fats; glucose is the body's major source of energy, is transported to cells via the circulation and used by cells in the presence without penetrating the skin, Garg says. "I think the major advance [in monitoring] in the next 5 years is going to be in this technology," he says. The GlucoWatch, made by Cygnus of Redwood City Redwood City, city (1990 pop. 66,072), seat of San Mateo co., W Calif., on San Francisco Bay; inc. 1868. Manufactures include commmunications, electrical, electronic, and medical equipment. , Calif., is expected to sell for about $300, with the pad costing $4 per day to replace. The diabetes patients reported some mild itching and irritation under the pad. Garg notes that the watch, which uses a AAA battery, can be moved each day to minimize this side effect. Cygnus has sent data from 600 patients to the Food and Drug Administration as part of an application for marketing approval. |
|
||||||||||||||||

Printer friendly
Cite/link
Email
Feedback
Reader Opinion